台股 » 個股 » 神隆 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

神隆

(1789)
可現股當沖
  • 股價
    23.10
  • 漲跌
    ▲0.25
  • 漲幅
    +1.09%
  • 成交量
    664
  • 產業
    上市 生技醫療類股
  • 299人加入追蹤

    立即追蹤

  • 本地時間:14:30(已收盤)

     
神隆 (1789)籌碼相關-永豐金-埔里 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

永豐金-埔里 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/02/25522.97223.0523.0034320.69%
2025/02/24423.2800.0023.1544230.95%
2025/02/21423.2500.0023.2544250.94%
2025/02/20223.0500.0023.3024190.48%
2025/02/191223.12223.5023.35104082.45%
2025/02/1800.00222.6022.65-2374-0.53%
2025/02/1400.00222.9822.95-2377-0.53%
2025/02/1300.00222.8022.80-2384-0.52%
2025/02/10222.5000.0022.5523830.52%
2025/02/07622.7000.0022.7063951.52%
2025/02/0600.00322.9722.95-3390-0.77%
2025/01/1700.00222.4522.35-2394-0.51%
2025/01/150.222.0500.0022.100.23940.05%
2025/01/140.822.0800.0022.000.83920.20%
2025/01/0300.00421.8022.00-4360-1.11%
2024/12/31122.0000.0022.0513630.27%
2024/12/26122.7000.0022.5513660.27%
2024/12/25422.2800.0022.3543661.09%
2024/12/0300.00223.8023.80-2366-0.55%
2024/12/02223.4000.0023.5023650.55%
2024/11/29423.4500.0023.4043651.09%
2024/11/27223.3000.0023.3523690.54%
2024/11/1500.000.123.1523.05-0.1375-0.02%
2024/11/06123.6500.0023.5513600.28%
2024/10/22224.45124.4524.5014080.24%
2024/10/21124.65224.6524.60-1414-0.24%
2024/10/1800.00224.7524.65-2436-0.46%
2024/10/11224.6000.0024.6524810.42%
2024/10/09224.8500.0024.8525110.39%
2024/10/08124.85225.1024.85-1528-0.19%
2024/10/07124.9500.0025.0015360.19%
2024/09/26225.2500.0025.2525960.34%
2024/09/2500.00125.5025.55-1621-0.16%
2024/09/2400.00225.2825.30-2635-0.31%
2024/09/13124.5000.0024.7016890.15%
2024/09/05124.60124.4524.1507720.00%
2024/08/3000.00225.7525.75-2832-0.24%
2024/08/27225.3500.0025.3028620.23%
2024/08/02125.8000.0025.7511,0960.09%
2024/07/31225.9000.0025.9021,1040.18%
2024/07/29225.9000.0025.8521,1170.18%
2024/07/26126.0500.0026.0511,1310.09%
2024/07/23226.5000.0026.4021,1770.17%
2024/07/22226.00226.3526.5001,1950.00%
2024/07/18226.8500.0026.8521,1880.17%
2024/07/17227.1500.0027.1021,1920.17%
2024/07/15227.4500.0027.2021,2110.17%
2024/07/12327.70327.8727.6001,2090.00%
2024/07/11627.6500.0027.4561,2150.49%
2024/07/10528.2400.0028.0551,2080.41%
2024/07/09428.5600.0028.6541,2050.33%
2024/07/0500.00229.0028.90-21,239-0.16%
2024/07/03228.8500.0028.9021,3010.15%
2024/07/01129.50229.5829.45-11,343-0.07%
2024/06/27128.8500.0028.9511,3240.08%
2024/06/2600.00129.1529.10-11,371-0.07%
2024/06/24228.3000.0028.2521,4890.13%
2024/06/20228.7000.0028.4021,4910.13%
2024/06/1700.00129.3029.10-11,547-0.06%
2024/06/14328.8500.0028.8031,5370.20%
2024/06/1100.00129.3529.20-11,538-0.06%
2024/06/06228.45228.9828.5001,5040.00%
2024/06/0500.00129.2028.90-11,512-0.07%
2024/05/31627.9800.0027.8561,4970.40%
2024/05/29328.3700.0028.1531,4980.20%
2024/05/2800.00128.1528.50-11,491-0.07%
2024/05/21329.48230.3029.3511,4530.07%
2024/05/2000.00229.2029.35-21,387-0.14%
2024/05/1700.00628.4528.60-61,341-0.45%
2024/05/10127.7500.0027.5511,3060.08%
2024/05/09327.5800.0027.6031,2990.23%
2024/05/02228.70228.8028.6501,2570.00%
2024/04/2900.00129.0029.10-11,228-0.08%
2024/04/26228.10228.4528.1501,1760.00%
2024/04/25128.10228.2028.20-11,158-0.09%
2024/04/2300.00128.0028.00-11,161-0.09%
2024/04/2200.00227.3027.45-21,154-0.17%
2024/04/19326.8300.0026.7531,1470.26%
2024/04/1700.00127.8527.75-11,126-0.09%
2024/04/1500.00127.7527.45-11,111-0.09%
2024/04/12627.4000.0027.4561,0970.55%
2024/04/11528.0900.0028.0551,0690.47%
2024/04/10128.75128.5028.7001,0400.00%
2024/04/09327.72127.8027.8029850.20%
2024/04/08228.25228.4828.3009620.00%
2024/04/01127.5000.0027.4518850.11%
2024/03/29427.83128.1527.6538760.34%
2024/03/28128.10627.3627.65-5821-0.61%
2024/03/2700.00526.6226.65-5699-0.72%
2024/03/2500.00126.6026.35-1685-0.15%
2024/03/2000.00826.4326.70-8661-1.21%
2024/03/19225.40425.7025.75-2606-0.33%
2024/03/18225.5000.0025.4026070.33%
2024/03/15126.05426.0926.10-3589-0.51%
2024/03/1400.00125.9026.00-1580-0.17%
2024/03/1200.00225.5825.60-2576-0.35%
2024/03/0600.00125.3525.25-1572-0.17%
漢達私募引進神隆成第二大股東 攜手拓展改良型新藥Anue鉅亨-2024/12/20
神隆 相關文章